SD-OCT measurements of RNFL thickness may help predict likelihood of glaucoma diagnosis

Article

Researchers have developed a methodology for calculating likelihood ratios for glaucoma diagnosis using continuous retinal nerve fiber layer (RNFL) thickness measurements taken with spectral-domain optical coherence tomography (SD-OCT), and found that average RNFL thickness values < 86 ?m were associated with negative likelihood ratios of such a diagnosis.

La Jolla, CA-Researchers have developed a methodology for calculating likelihood ratios for glaucoma diagnosis using continuous retinal nerve fiber layer (RNFL) thickness measurements taken with spectral-domain optical coherence tomography (SD-OCT), and found that average RNFL thickness values

For this observational cohort study, researchers from the Hamilton Glaucoma Center at the University of California, San Diego, recruited a total of 187 patients (262 eyes) with glaucoma and 100 controls (190 eyes) from the Diagnostic Innovations Glaucoma Study. In the glaucoma group, eyes with preperimetric and perimetric glaucomatous damage were included, while the control group was comprised of healthy eyes with normal visual fields in subjects recruited from the general population.

All eyes underwent RNFL imaging with SD-OCT. Using a methodology based on estimating the tangents to the receiver operating characteristic (ROC) curve, researchers estimated the likelihood ratios for a diagnosis of glaucoma for specific global RNFL thickness measurements.

Likelihood ratios were possible for continuous values of average RNFL thickness, and average RNFL thickness values

The abstract can be accessed: here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.